Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 870 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Degarelix Accord September 14, 2023 Why is Colorectal Cancer Rising Rapidly among Young Adults? November 5, 2020 Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC April 19, 2022 When You and Your Child Have VHL: 8 Ways to Cope August 11, 2020 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel Inseparable Couples Dies 33 Hours Apart After 68 Years Of Marriage:... An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling... Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients...
